Brief: Allergy Therapeutics Announces Grass Mata Mpl Phase III Data Published In Allergy
17/02/2025 07:27
Feb 17 (Reuters) - Allergy Therapeutics PLC AGY.L :
* GRASS MATA MPL PHASE III DATA PUBLISHED IN ALLERGY
* PHASE III TRIAL SHOWS 20.3% REDUCTION IN CSMS COMPARED TO
PLACEBO
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Allergy Therapeutics
See all newsBrief: Allergy Therapeutics Expects FY 2026 Revenue Of £59.90 Million, Up 9% Reported
UK's Allergy Therapeutics FY revenue beats on Grassmuno launch
Allergy Therapeutics - Trading update for the year ended 30 June 2026
Brief: Allergy Therapeutics Appoints Helge Weiner-Trapness As Executive Chairman
Allergy Therapeutics - Appointment of Executive Chairman